Beyond Clinical Trials: Experience with Bimekizumab in 3 Challenging Cases of Psoriatic Arthritis
These real-world cases support the efficacy and tolerability of bimekizumab across diverse and complex PsA presentations. Dual IL-17A/F inhibition may provide a valuable therapeutic option for patients with refractory disease, comorbidities, or rare phenotypes.
Authors
- Marina Papoutsaki (ORCID: https://orcid.org/0000-0002-2422-0994)
- Christos Koutsianas (ORCID: https://orcid.org/0000-0002-6621-6918)
- Theodoros Dimitroulas (ORCID: https://orcid.org/0000-0002-0364-1642)
- Ioanna Katsigianni (ORCID: https://orcid.org/0009-0002-9747-4466)
- Michail Visvikis
- Evangelos Papadimitriou
Institutions
- Democritus University of Thrace (GR)
- National and Kapodistrian University of Athens (GR)
- Aristotle University of Thessaloniki (GR)
- Andreas Sygros Hospital (GR)
- University Hospital of Alexandroupolis (GR)
Publication Details
- Journal
- Mediterranean Journal of Rheumatology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.31138/mjr.071125.est
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00